Developing treatment for spinal and bulbar muscular atrophy

Area of Science:

• Neuroscience
• Genetics
• Endocrinology

Background:

• Spinal and bulbar muscular atrophy (SBMA) is a polyglutamine disease.
• Mutant androgen receptor (AR) protein toxicity is ligand-dependent in SBMA.
• Pathological mechanisms include protein aggregation, altered transcription, and impaired axonal transport and mitochondrial function.

Purpose of the Study:

• To review the unique ligand-dependent toxicity of mutant AR in SBMA.
• To summarize therapeutic strategies investigated in SBMA models.
• To discuss the implications of past clinical trials for future SBMA research.

Main Methods:

• Review of cell culture and animal models of SBMA.
• Analysis of therapeutic approaches targeting mutant AR.
• Evaluation of clinical trial outcomes for androgen-reducing agents.

Main Results:

• Mutant AR causes aggregation, transcriptional dysregulation, and axonal transport and mitochondrial deficits.
• Therapies like androgen reduction, HSP90 inhibitors, IGF-1, and ASC-J9 show efficacy in mouse models.
• Clinical trials of androgen reduction indicate potential but lack definitive clinical benefit.

Conclusions:

• SBMA's ligand-dependent mutant AR toxicity presents unique therapeutic challenges.
• Preclinical findings support further investigation of diverse therapeutic agents in SBMA.
• Future clinical studies will build upon existing trial experiences and emerging preclinical data.